Lazertinib+Pemetrexed+Carboplatin
Sponsors
Yonsei University
Conditions
Non Small Cell Lung CancerNon-small Cell Lung Cancer
Phase 2
Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy
NCT06020989
Start: 2023-09-30End: 2025-12-31Target: 129Updated: 2023-09-01
Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer
Active, not recruitingNCT06268210
Start: 2022-02-07End: 2028-06-01Target: 160Updated: 2026-07-07